Upcoming events

Apr 2017

2017-04-01 00:00:00.000000
7-9 Apr 2017
PCR Tokyo Valves 2017

Tokyo

Japan

May 2017

2017-05-01 00:00:00.000000
16-19 May 2017
EuroPCR 2017

Paris

France

Supported by

TAVI (Transcatheter aortic valve implantation)

Here you will find all the latest content on transcatheter aortic valve implantations (TAVI) published on this website. Results are listed in chronological order.

TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients. This topic covers the newest devices and emerging data in TAVI as well as information on tools, devices and techniques such as vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography, understanding bleeding risks or patient selection. Find out more…

Filtered By
TAVI

504 results

Highlights from ACC 2017

How important was interventional cardiology at this year’s American College of Cardiology Scientific sessions? Join D. Capodanno as he reviews the breaking sessions and others to reveal what aspects of our specialty were touched on during this recent international meeting and why. From structural and coronary to imaging, as well as important developments in pharmacology see which issues had the greatest impact: Was it iFR or FFR?  TAVI? New agents? Cost effectiveness?  Get your “take-home” message here…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).

What to expect in interventional cardiology in 2017

PCR Chair William Wijns gives us his take on 2017: expanded indications for TAVI, new BRS data, trials on device based therapies in arterial hypertension, launch of Stent Save a Life, slow implementation of interventional treatment of acute ischemic stroke, celebrating 40 years of balloon angioplasty and EuroPCR 2017. An exciting year lies ahead!

RESOLVE and SAVORY: subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic aortic valves

Better understanding of reduced leaflet motion in bioprosthetic aortic valves due to subclinical leaflet thrombosis is critical, and R. Makkar discusses two, single hospital registries which look at this phenomenon. Is there a difference between surgical and transcatheter aortic valves? Can DAPT strategies or the use of non-vitamin K antagonist anticoagulants (NOACs) play a role here? What is the effect of this phenomenon on clinical outcomes? Death rates? Strokes? Transient ischaemic attacks? Can these findings impact future guidelines concerning aortic valve replacement? Learn more…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).

Lessons from the SURTAVI trial - ACC.17

International in scope, demonstrating non-inferiority as a goal, this trial uses an early iteration of the CoreValve and the new Evolut-R bioprosthesis. Join M. Gilard as she captures the key message of SURTAVI, the second trial to compare TAVI to surgery in intermediate risk patients. Learn what was the observed rate of mortality, stroke, paravalvular leak or pacemaker use and understand why this can have an impact on future guidelines for patients eligible for TAVI. Learn more today…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).

SURTAVI: TAVI versus surgery in intermdiate risk AS patients

Your patient has symptomatic, severe aortic stenosis and an intermediate level of operative risk – how would you treat them? Surgery? What if TAVI was shown to be as safe and effective as the surgical approach, even in these lower risk patients? Join M. J. Reardon as he explains the results of a trial that can impact our future use of TAVI. Learn how levels of risk were defined and how the results further support the aspirations of this technique and the newer generation of devices used here…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

SURTAVI: Should TAVI become class I for intermediate-risk patients with severe aortic stenosis?

18 Mar 2017

ACC.17 Late breaking clinical trial:  Transcatheter Aortic Valve Replacement with a self-expanding bioprothesis compared with surgical aortic valve replacement in patients at intermediate surgical risk: first results from the SURTAVI clinical trial Michael REARDON, Houston

LIVE case: TAVI in a bicuspid aortic valve

From PCR London Valves 2016

Consult this LIVE case if you want to learn more about TAVI in a bicuspid aortic valve.

Clinical case

A 74-year-old male with bicuspid aortic stenosis:

  • Conscious sedation
  • Transfemoral access
  • With pre dilatation

Operator

Stefan Stortecky
Prof. Stefan Windecker

Operator

Stephan Windecker

TAVI for severe symptomatic AS in presence of mechanical mitral valve replacement

27 Feb 2017

 
A 74 year old Chinese female with significant past history of severe mitral regurgitation secondary to mitral valve prolapse treated mechanical mitral valve replacement in 1997 and atrial fibrillation was admitted for breathlessness and heart failure.

Kay-Woon Ho

Author

Kay-Woon Ho
Soon Jia Lin

Author

Jia-Lin Soon

EIJ: TAVI and mitral clip

26 Apr 2016

Article on Everest II 5 years by T. Feldman extracted from the Journal of the American College of Cardiology

PCR Tokyo Valves Learning from 2016, perspectives for 2017

Understanding the expansion of transcatheter valve therapies in Asia is not just a question of knowledge, experience and technique, but also the cultural, economic and anatomical differences that are specific to the region.

Learn why as P. MacCarthy from the UK with K. Hayashida from Japan, H-L Kao of Taiwan, and K. K. Yeo from Singapore discuss current Asian practice. Are there different complications facing Asian specialists? Is there a specific appeal among Asian patients to the noninvasive approach? What is the status of noninvasive mitral interventions? Learn the answers to these and other questions - and how PCR Tokyo Valves is expanding to become the Asian forum in this field…